FORWARD LOOKING STATEMENTS

Sirona Biochem cautions you that statements included in this presentation that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investment Highlights</td>
<td>4</td>
</tr>
<tr>
<td>Share Information</td>
<td>5</td>
</tr>
<tr>
<td>Business Model Strategy</td>
<td>6</td>
</tr>
<tr>
<td>Business Model Success</td>
<td>7</td>
</tr>
<tr>
<td>Product Pipeline</td>
<td>8</td>
</tr>
<tr>
<td>Worldwide IP Portfolio</td>
<td>11</td>
</tr>
<tr>
<td>Milestones</td>
<td>12</td>
</tr>
<tr>
<td>Our Next Big Thing</td>
<td>13</td>
</tr>
<tr>
<td>Facilities/M. Partners</td>
<td>16</td>
</tr>
<tr>
<td>Technology</td>
<td>17</td>
</tr>
<tr>
<td>Management</td>
<td>20</td>
</tr>
<tr>
<td>Contact Us</td>
<td>22</td>
</tr>
<tr>
<td>Sources</td>
<td>23</td>
</tr>
</tbody>
</table>
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Through its wholly-owned French subsidiary TFChem, the Company specialises in stabilising carbohydrate molecules with the goal of improving efficacy and safety. Sirona Biochem’s business model is to develop active ingredients that are then licensed out for up front payments, milestones and royalties.

**INVESTMENT HIGHLIGHTS**

- **Signed** global exclusive licensing deal with Allergan Aesthetics, an AbbVie [NYSE: ABBV] company, for TFC-1067 and library of cosmetic compounds. [3]

- **Ongoing royalty payments** for compound discoveries, including upcoming royalties on net sales generated by AbbVie product line based on licensed patented ingredients. Cooperating on additional products with AbbVie. **17 years** duration for TFC-1067 patents.

- **Disruptive** proprietary carbohydrate-bonding platform based on 20 years of research and development.

- Strong worldwide IP portfolio, including North America, European Union, and Asia.

- **Cosmetics** - Developing disruptive solutions for anti-aging ($271B USD) [5], cell preservation ($7.5B USD) [7], and cellulite treatment ($1.4B USD) [8].

- **Pharmaceutical** - TFC-039, first-in-market ingestible tablet to treat animal diabetes. In advanced partnership talks with four major animal health companies.

  - Developing Anti-viral TBD compound for $36B USD anti-viral market. [9]

- State-of-the-art, multi-million dollar laboratory in France with top scientific team, strong global manufacturing partners for pharmaceutical (Wanbang Pharma, China) and cosmetics (Wuxi AppTec, China).
# SHARE INFORMATION

<table>
<thead>
<tr>
<th>Exchange</th>
<th>Symbol</th>
<th>CAD</th>
<th>USD</th>
<th>EUR</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSX-VENTURE</td>
<td>SBM</td>
<td>0.21</td>
<td>0.17</td>
<td>0.15</td>
</tr>
<tr>
<td>OTCQB</td>
<td>SRBCF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FRANKFURT STOCK</td>
<td>ZSB</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## FUNDAMENTAL DATA (CAD)

- **TSX-V**
  - Shares Outstanding: 250,251,526
  - Shares Fully Diluted: 275,187,486
  - Share Price (CAD): 0.22
  - Market Cap: 55,055,335
  - Year High: 0.29
  - Year Low: 0.14

*Friday - June 10, 2022

- **Our Management has skin in the game**
  - **Dr. Howard V.**
    - CEO - BOD Chairman
    - Shares owned: 5.2M
    - Options: 2.5M

- **Dr. Geraldine D.**
  - Chief Scientific Officer
  - Shares owned: 3.8M
  - Options: 3.8M

- **Christopher H.**
  - Chief Financial Officer
  - Shares owned: 1.23M
  - Options: 3.8M
Sirona Biochem’s strategy is to license or sell patented compounds to leading global companies in return for up-front fees, milestone fees and ongoing royalty payments.
Allergan Aesthetics, an AbbVie [NYSE: ABBV] company, signed a global exclusive licensing deal with Sirona Biochem for its library of breakthrough compounds including TFC-1067 [3]
Sirona Biochem has invested extensively in developing its products to meet the need of patients and industry partners. The compounds created through our proprietary platform go through rigorous tests and regulatory scrutiny to verify their safety and efficacy.
## COSMETIC PRODUCTS

<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>Compound</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skincare - Dark spot corrector (Rx &amp; OTC)</td>
<td>TFC-1067 &amp; family of dark spot correctors</td>
<td>• Exclusive licensing deal with AbbVie for TFC-1067 signed [3]</td>
</tr>
<tr>
<td>Cell Preservation &amp; Repair (incl keloid &amp; scar therapy)</td>
<td>Glycoprotein Library</td>
<td>• Rodan + Fields licensed 2019; first product launched [2]</td>
</tr>
<tr>
<td>Skincare - Anti-Aging/Anti-wrinkle</td>
<td>TFC-1326</td>
<td>• In vitro testing for lead determination</td>
</tr>
<tr>
<td>Skincare - Cellulite Treatment</td>
<td>TBA</td>
<td>• Completed safety studies - awaiting dose approval and batch manufacturing for clinical trial [4]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• In discussion for R&amp;D partnership</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Ongoing research &amp; development</td>
</tr>
</tbody>
</table>

## ESTIMATED MARKET SIZE

- Skincare - Dark spot corrector (Rx & OTC): $8B USD [6]
- Cell Preservation & Repair (incl keloid & scar therapy): $7.5B USD [4]
- Skincare - Cellulite Treatment: $1.45B USD [8]
### PHARMACEUTICAL PRODUCTS

<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>Compound</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes &amp; Other (SGLT2 inhibitor)</td>
<td>TFC-039</td>
<td>• In advanced discussions w/ four major interested parties from the animal health sector</td>
</tr>
<tr>
<td>Anti-viral</td>
<td>TBD (from library)</td>
<td>• Finalizing patent for new indication, preparing sector</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• planning next studies</td>
</tr>
</tbody>
</table>

### ESTIMATED MARKET SIZE

<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>Market Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Viral</td>
<td>$36.98B USD</td>
</tr>
<tr>
<td>Diabetes &amp; Other (SGLT2 inhibitor)</td>
<td>$7.2B USD</td>
</tr>
</tbody>
</table>

*Sirona Biochem* is continually discovering new compounds and molecules, with the goal of advancing global medicine and health care.
Sirona Biochem has a strong IP portfolio, including a recently filed patent for its breakthrough anti-aging compound TFC-1326, managed by intellectual property law firm Cabinet Regimbeau.
MILESTONES

Milestones achieved in the last 18 months:

✓ Completed an exclusive, global license with AbbVie for TFC-1067
✓ Completed the terms of manufacturing and supply of TFC-1067 for AbbVie
✓ Published research in the renowned Journal of Cosmetic Dermatology [13]
✓ Reached first product commercialization with TFC-1067 [2]
✓ Discovered potential anti-cellulite activity in compounds
✓ Completed preclinical work for anti-aging compound and established batch scale-up for clinical trial [14]
✓ Signed agreement with Pullan Consulting for negotiation and strategy on TFC-1067 [15]
✓ Developed 20 novel antiviral compounds for library and completed initial screening for covid activity
✓ Completed a significant patent extension for the anti-aging compounds

Sirona is working intensively towards achieving the following milestones:

• Finalize an agreement for the SGLT2 inhibitor in animal health
• Enter advanced negotiations for the SGLT2 inhibitor for human health in new territory
• Advance and patent the SGLT2 inhibitor in third therapy area
• Advance the anti-aging compounds to clinical study with potential pharma R&D partner
• Secure non-dilutive funding through grants
• File patents around novel compounds and therapy areas of interest
• Advance the anti-viral compounds into preclinical studies with new R&D collaboration [16]

*The milestones listed are not in chronological order. The achievement of milestones is mostly dependent on external partners and factors over which we have limited control. Accordingly, we will no longer provide a precise time estimate. We will immediately update shareholders on material items as they arise.
It’s estimated that 1.7 million cats will develop diabetes. Treatment is needed to manage their condition, often requiring twice-daily injections.

Pet ownership rose sharply during the COVID-19 pandemic, pushing the animal health care market to more than $139 billion and is predicted to grow at over 4.7%.

Sirona intends to be one of the first companies to bring a solution to the market.
**INDUSTRY SOLUTION**

**Injections** are inconvenient for owners and painful for pets. A **diabetes pill** made from **Sirona’s TFC-039 compound** solves that problem and keeps pets healthy and happy.

**Sirona** has the solution to address this problem.

---

**Top 5 Animal Pharmaceutical Companies and Revenue**

<table>
<thead>
<tr>
<th>Company</th>
<th>Revenue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Merck</td>
<td>$47.99B USD</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>$22B USD</td>
</tr>
<tr>
<td>Zoetis</td>
<td>$7.78B USD</td>
</tr>
<tr>
<td>Covertus</td>
<td>$4.33B USD</td>
</tr>
<tr>
<td>Elanco</td>
<td>$3.27B USD</td>
</tr>
</tbody>
</table>
OUR NEXT BIG THING: Anti-Aging - TFC-1326

TFC-1326 Compound Library

The anti-aging market is forecasted to reach $271 Billion by 2024, with anti-wrinkle accounting for 59.3% of the total share.

Sirona just filed a patent for its glycopeptides treatment, which rejuvenates and restores the skin’s youthful glow by significantly increasing lipid synthesis.

Our next big breakthrough compound

TFC-1326 could become the industry's new go-to active ingredient to reverse skin aging by smoothing wrinkles and repairing skin damage. The technology could also be potentially applied to other cosmetic categories such as hair care, makeup and suncare.
FACILITIES/MANUFACTURING PARTNER

Sirona Biochem Laboratory

TFChem Laboratory, France

The 502-square-meter laboratory is located in Val de Reuil, France. This state-of-the-art facility is located in France’s Cosmetic Valley, where the world’s leading cosmetic companies conduct their research and development.

The award-winning team working at the facility specializes in developing fluorinated building blocks, which addresses the limitations usually associated with the application of carbohydrate-based molecules as active ingredients.

www.sironabiochem.com

Anti-aging: TFC-1326 Laboratory

DIVA Laboratory, France

We’re currently working with DIVA on anti-aging.

www.diva-expertise.com

WuXi AppTec, China

WuXi AppTec provides a broad R&D and manufacturing services portfolio that enables the global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients.

The company has research, development, and manufacturing facilities in China, South Korea, the U.S., Germany, the UK, Switzerland, and Israel.

www.wuxiapptec.com

Manufacturing Partner - TFC-039

Wanbang Pharma, China

Wanbang Biopharma has established a domestic first-class R&D and manufacturing site in China for genetic engineering drugs of prokaryotic and eukaryotic cells.

The company employs more than 300 highly-educated professionals at its more than seven manufacturing sites across China, with a total area of more than 675,000 square meters.

www.chinawanbang.com

Manufacturing Partner - TFC-1067

WuXi AppTec, China

www.wuxiapptec.com
Our world-class team is comprised of award-winning scientists who have worked for Fortune 500 companies such as Sanofi, GSK and Bayer.
Carbohydrate compounds have immense commercial potential.

- They are involved in many of our body’s biological processes and are also used for development of active ingredients in pharmaceuticals and cosmetics

Examples of successful carbohydrate-based drugs are:

- Anti-viral medications such as Tamiflu, used for the treatment of Influenza A

- Blood thinners, such as Arixtra and Lovenox, for the treatment of blood clots
  - Lovenox: sales of $1.46 Billion USD (2018) [25]

Our Technology has received more than $8M CAD in grants from the French Government, including new financing to develop its advance chemistry process.
The challenges with carbohydrates are:

- Carbohydrates have complex syntheses requiring expert chemists
- Carbohydrates are unstable, causing lower efficacy or toxic by-products
- Carbohydrates have poor pharmacological properties

Sirona Biochem’s proprietary chemistry increases the potential and reduces the drawbacks of carbohydrate molecules.

- Sirona’s Fluorination Chemistry Technology is the solution to unstable carbohydrate molecules.

- The chemistry strengthens the bonds of a carbohydrate molecule by strategically placing fluorine atoms.

Carbohydrate molecules are unstable by nature

Sirona’s technology stabilizes carbohydrate molecule
Dr. Verrico obtained his medical degree from the University of Toronto in 1985 and has been a member of the College of Physicians and Surgeons of British Columbia since July 1986. Dr. Verrico has extensive experience as a venture capitalist in the junior capital markets. He has acted as a venture capitalist for over 30 years, funding numerous start-ups and early-stage companies both in the private and public marketplace. He is the original founder of Sirona Biochem building the company by investing his personal funds starting in 2006. He has accumulated his large share position through personal share purchases. He currently is solely focused on the success and growth of SIRONA Biochem as it enters a stage of rapid growth.

Dr. Géraldine Deliencourt-Godefroy is an award-winning synthetic chemist and the founder of French-based biotechnology company TFChem. Since the acquisition of TFChem by Sirona Biochem in March 2011, Dr. Deliencourt-Godefroy has assumed the role of Chief Scientific Officer. Her scientific research in carbohydrate chemistry has led to the discovery of new drug families and the development of drug candidates for diabetes and obesity, cosmetic ingredients and biological adjuvants. Previous to founding TFChem, Dr. Deliencourt-Godefroy was a scientific leader at INSA (National Institute of Applied Sciences) in Rouen, France, where she developed a new technology for stabilized carbohydrates. Previous roles also include a post-doctoral position at the University College London and doctoral research at the Research Institute of Fine Organic Chemistry in Rouen, France. Dr. Deliencourt-Godefroy received a PhD and Masters in Organic Chemistry as well as her business degree from the University of France. She is the author of several publications and patents and is also the recipient of the acclaimed Francinov Research and Innovation Medal, French Ministry of Research Award and the French Senate Award.
Christopher Hopton, Sirona Biochem’s Chief Financial Officer, brings 28 years of expertise in financial management and operations. His extensive experience covers areas of financial planning, accounting policy and business process improvement. As a business investment and finance consultant, Mr. Hopton has worked with several public and privately-held companies. Most recently, Mr. Hopton was the Chief Financial Officer of Central Resources Corp., a junior mineral exploration company. Formerly, he held the position of Division Controller at Canadian Airlines where he was responsible for an annual operating budget of $200M. Mr. Hopton was also involved in the restructuring of 360 Networks, a network communications company, which led to a buyout by Bell Canada. Mr. Hopton earned his Bachelor of Business Administration from Simon Fraser University in British Columbia, Canada and received his professional designation as a Certified General Accountant.

Michelle Seltenrich brings 21 years of expertise in publicly traded biotech companies. Her experience ranges from both academic and industrial R&D lab management to corporate mergers and acquisitions. Ms. Seltenrich was previously the Manager of Business Development at Forbes MediTech, a NASDAQ traded company, where she was responsible for international business development, in-licensing and M&A. She co-led a team in the successful acquisition of a U.S.-based biotech company. Ms. Seltenrich holds a BSc from the University of British Columbia and an MBA in Technology Management from Simon Fraser University.
CONTACT US

Sirona Biochem: Corporate Office
Parent Company - founded 2009

Sirona Biochem Corp.
c/o WeWork
595 Burrard Street,
Vancouver, BC
V7X 1L4

PHONE: +1.604.641.4466
EMAIL: info@sironabiochem.com
WEBSITE: www.sironabiochem.com

TFChem: Laboratory
Wholly Owned Subsidiary - acquired in 2011

TFChem
Voie de l’innovation
Pharma Parc II
27100 Val de Reuil
France

PHONE: +33(0)2.32.09.01.16
FAX: +33(0)2.32.25.07.64
EMAIL: contact@tfchemistry.com